Page 103 - 80_01
P. 103

Class	
  I	
  phosphoinositide	
  3-­-kinases	
  in	
  immunity…	
  

	
  
6.	
  PI3K	
  INHIBITORS	
  OF	
  BROAD	
  AND	
  RESTRICTED	
  SPECIFICITY.	
  IMPORTANCE	
  TO	
  

    CANCER.	
  

        Hence,	
  PI3K	
  inhibitors,	
  or	
  inhibitors	
  of	
  PI3K	
  targets	
  like	
  Akt	
  or	
  mTOR,	
  have	
  
been	
   actively	
   looked	
   for	
   as	
   anti-­-cancer	
   drugs	
   (see	
   (51),	
   for	
   a	
   recent	
   review).	
   In	
  
these	
   assays	
   p110a-­-,	
   p110ß-­-,	
   p110d-­-,	
   p110?-­-,	
   dual	
   p110?/d-­-specific	
   or	
   pan-­-PI3K	
  
inhibitors,	
   as	
   well	
   as	
   dual	
   PI3K-­-mTOR	
   inhibitors	
   are	
   under	
   investigation	
   in	
  
experimental	
  tests	
  and	
  clinical	
  trials.	
  	
  

7.	
  ROLE	
  OF	
  CLASS	
  IA	
  AND	
  CLASS	
  IB	
  PI3KINASES	
  IN	
  THE	
  CONTROL	
  OF	
  IMMUNE	
  
    RESPONSES.	
  GENETIC	
  MODELS	
  AND	
  PI3K	
  INHIBITORS	
  

        The	
   relevance	
   of	
   class	
   IA	
   PI3K-­-mediated	
   signals	
   to	
   all	
   steps	
   of	
   innate	
   and	
  
adaptive	
   immune	
   responses	
   immediately	
   point	
   to	
   the	
   potential	
   relevance	
   of	
  
inhibitors	
  of	
  PI3K	
  or	
  of	
  PI3K	
  effectors	
  as	
  immunomodulators	
  and	
  therapeutic	
  tools	
  
in	
  many	
  socially	
  relevant	
  immune-­-mediated	
  diseases	
  (17,18,22,52-­-56).	
  The	
  role	
  of	
  
PI3K	
   in	
   immunity	
   has	
   been	
   analyzed	
   in	
   vivo	
   by	
   the	
   generation	
   of	
   mice	
   lacking	
  
specific	
   regulatory	
   and	
   catalytic	
   subunits,	
   or	
   expressing	
   kinase-­-dead	
   mutants	
   of	
  
specific	
   subunits,	
   or	
   by	
   means	
   of	
   specific	
   inhibitors	
   of	
   PI3K	
   or	
   its	
   downstream	
  
signaling	
   targets.	
   In	
   vitro	
   the	
   analysis	
   has	
   involved	
   cell	
   lines	
   derived	
   from	
   the	
  
above	
   models,	
   specific	
   inhibitors,	
   and	
   knock-­-down	
   approaches	
   using	
   siRNA.	
   We	
  
shall	
   now	
   review	
   the	
   genetic	
   and	
   pharmacological	
   data	
   that	
   supports	
   this	
  
immunomodulatory	
  potential	
  in	
  the	
  adaptive	
  immune	
  response	
  mediated	
  by	
  B	
  and	
  
T	
  lymphocytes.	
  

8.	
  CLASS	
  IA	
  AND	
  IB	
  PI3K	
  IN	
  IMMUNITY:	
  LESSONS	
  FROM	
  GENETIC	
  STUDIES	
  IN	
  B	
  
    LYMPHOCYTES.	
  	
  

        B	
   lymphocytes	
   are	
   an	
   essential	
   arm	
   of	
   the	
   adaptive	
   immune	
   responses	
   as	
  
the	
   cells	
   responsible	
   of	
   antibody	
   responses	
   against	
   pathogens;	
   antibodies	
   are	
  
produced	
   in	
   great	
   quantities	
   by	
   the	
   B-­-cell	
   derived	
   plasma	
   cells.	
   The	
   quality	
   of	
   the	
  
antibodies	
   both	
   in	
   terms	
   of	
   their	
   affinity	
   for	
   the	
   antigen	
   and	
   the	
   class	
   of	
   the	
  
constant	
   regions	
   is	
   essential	
   to	
   efficient	
   removal	
   of	
   parasites,	
   and	
   is	
   largely	
  
determined	
   by	
   the	
   cytokines	
   in	
   the	
   milieu,	
   particularly	
   those	
   secreted	
   by	
   antigen-­-
specific	
   T	
   helper	
   cells.	
   Mature	
   B	
   lymphocytes	
   exist	
   in	
   two	
   major	
   subsets,	
   namely	
  
the	
   B-­-1	
   cells	
   found	
   in	
   body	
   cavities	
   like	
   the	
   peritoneum	
   that	
   have	
   innate	
  
properties,	
  and	
  the	
  B-­-2	
  cells	
  that	
  comprise	
  non-­-recirculating	
  MZ	
  (marginal	
  zone)	
  B	
  
cells	
   and	
   the	
   FO	
   (follicular)	
   B	
   cells	
   that	
   recirculate	
   through	
   the	
   blood	
   and	
  
secondary	
  lymphoid	
  organs.	
  	
  

        The	
   role	
   of	
   regulatory	
   subunits	
   has	
   been	
   analyzed	
   in	
   pan-­-p85a-­-/-­-	
   (p85a-­-/-­-,	
  
p55a-­-/-­-,	
   p50a-­-/-­-)	
   defective	
   mice,	
   lacking	
   all	
   p85a	
   isoforms.	
   These	
   mice	
   have	
  
perinatal	
   lethality,	
   assays	
   using	
   RAG2	
   chimeric	
   mice	
   with	
   hematopoietic	
   cells	
  

                                                                                                                            	
  101	
  

	
  
   98   99   100   101   102   103   104   105   106   107   108